Injectable Biochip for Sars-CoV-2 Detection Nears FDA Approval
The Silicon Valley company, Profusa,1 in partnership with the U.S. Defense Advanced Research Projects Agency (DARPA),2 has created an injectable biosensor capable of detecting the presence of an infection in your body.3
In early August 2019, months before COVID-19 became a household word, DARPA granted Profusa additional funding “to develop an early identification system to detect disease outbreaks, biological attacks and pandemics up to three weeks earlier than current methods.”4
As discussed in “Will New COVID Vaccine Make You Transhuman?” we appear to stand at the doorway of a brave new world in which man is increasingly merged with technology and artificial intelligence, and COVID-19 may well be the key that opens that door, in more ways than one.
For starters, many of the COVID-19 vaccines currently being fast-tracked are not conventional vaccines. Their design is aimed at manipulating your own biology, essentially creating genetically modified humans.
Combined with hydrogel biosensors — which do not suffer from rejection as foreign bodies like earlier implants, instead becoming one with your own tissue5 — we may also find ourselves permanently connected to the internet-based cloud, for better or worse.
Hydrogel Chip Will Connect You to the Internet
Hydrogel is a DARPA invention that involves nanotechnology and nanobots. This “bioelectronic interface” is part of the COVID-19 mRNA vaccines’ delivery system.
The biochip being developed by Profusa is similar to the proposed COVID-19 mRNA vaccines in that it utilizes hydrogel. The implant is the size of a grain of rice, and connects to an online database that will keep track of changes in your biochemistry and a wide range of biometrics, such as heart and respiratory rate and much more.
A September 2019 paper6 describes how the injectable sensor can help improve monitoring for peripheral artery disease. However, while it might be convenient, this kind of technology will also have immediate ramifications for our privacy. Who will collect and have access to all this data? Who will be responsible for protecting it? How will it be used, and when? As noted in a SteemKR article discussing the implants:7
“Along with the advent of in-body nanotechnology, and sensors which tie the human body to an artificial intelligence platform, the possibilities for misuse by totalitarian governments has not been lost on technology watchdogs. With advanced biosensors, artificial intelligence may be able to read the subject’s every mood and activity, heart rate, respiratory rate, body temperature, even sexual activity.”
How the Biosensor Works
In a March 3, 2020, article, Defense One explains the basics of how the biosensor works:8
“The sensor has two parts. One is a 3mm string of hydrogel, a material whose network of polymer chains is used in some contact lenses and other implants. Inserted under the skin with a syringe, the string includes a specially engineered molecule that sends a fluorescent signal outside of the body when the body begins to fight an infection.
The other part is an electronic component attached to the skin. It sends light through the skin, detects the fluorescent signal and generates another signal that the wearer can send to a doctor, website, etc. It’s like a blood lab on the skin that can pick up the body’s response to illness before the presence of other symptoms, like coughing.”
So, to recap, the technology consists of three components:9 the implanted sensor, a reader placed on the surface of the skin, and the software that allows the reader to send the collected data via Bluetooth to your phone or tablet, which in turn can be connected to other online sources such as your doctor’s website.
Detecting Outbreaks Before They Spread
As reported by Defense One,10 Profusa’s DARPA-backed technology will be able to detect the presence of flu-like infections — including SARS-CoV-2 infections — in the population before they become symptomatic. As such, the biosensors may well become part and parcel of future pandemic detection systems. Profusa hopes to gain Food and Drug Administration approval by early 2021.11
March 3, 2020, Profusa announced12,13 the launch of a study to investigate the technology’s effectiveness for early detection of influenza outbreaks. Collaborators include Duke University, the Imperial College of London and RTI International, a nonprofit research institute that develops algorithms for disease detection. According to the press release:14
“The study, conducted at Imperial College London, will examine how sensors monitoring physiological status, including the Lumee Oxygen Platform which measures tissue oxygen levels, provide potential indicators of human response to infection or exposure to disease in healthy volunteers.
The goal of the study is to develop an early identification system to detect not only disease outbreaks, but biological attacks and pandemics up to three weeks earlier than current methods. The results of the study are anticipated to be available in 2021.
‘This research marks an exciting step forward in the development of game-changing preventive care,’ said Ben Hwang, chairman and CEO of Profusa.
‘The Lumee Oxygen Platform can potentially function as a sort of canary in a coal mine for infectious disease, since subtle c
Article from LewRockwell